Resonance Health Limited (ASX:RHT)

Australia · Delayed Price · Currency is AUD

0.0380

-0.0070 (-15.56%)

At close: Mar 2, 2026

Revenue by Segment

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	Jun '19 Jun 30, 2019	Jun '18 Jun 30, 2018	Jun '17 Jun 30, 2017	Jun '16 Jun 30, 2016
Research & Development	5.27M	4.54M	-	-	-
Research & Development Growth	16.02%	-	-	-	-
Resonance Clinical	4.16M	3.93M	-	-	-
Resonance Clinical Growth	5.76%	-	-	-	-
Trialswest	2.66M	348.81K	-	-	-
Trialswest Growth	661.22%	-	-	-	-
Intersegment Elimination	-1.01M	-233.16K	-	-	-
Services	-	-	4.40M	3.83M	3.78M
Services Growth	-	-	15.06%	1.30%	3.02%
Total	11.07M	8.59M	4.40M	3.83M	3.78M
Total Growth	28.91%	95.02%	15.06%	1.30%	3.02%

Revenue by Geography

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	Jun '19 Jun 30, 2019	Jun '18 Jun 30, 2018	Jun '17 Jun 30, 2017	Jun '16 Jun 30, 2016
Asia/Pacific	2.75M	4.32M	293.89K	327.91K	156.62K
Asia/Pacific Growth	-36.40%	1369.51%	-10.38%	109.37%	35.97%
North America	2.03M	2.64M	2.78M	2.58M	1.17M
North America Growth	-23.11%	-5.19%	7.93%	120.60%	1.60%
EMEA	6.30M	1.64M	1.33M	920.74K	2.45M
EMEA Growth	285.25%	22.89%	44.52%	-62.49%	2.12%
South America	-	-	-	3.81K	-
Total	11.07M	8.59M	4.40M	3.83M	3.78M
Total Growth	28.91%	95.02%	15.06%	1.30%	3.02%

Source: S&P Global Market Intelligence.